Published in Lancet Oncol on November 17, 2015
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Recent advances in understanding multiple myeloma. F1000Res (2016) 0.78
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia (2016) 0.77
Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J (2017) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway. Oncol Lett (2016) 0.75
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer J (2016) 0.75
Continued role for ASCT in multiple myeloma. Lancet Oncol (2015) 0.75
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget (2016) 0.75
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol (2016) 0.75
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Korean J Intern Med (2016) 0.75
Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. J Cancer Res Clin Oncol (2016) 0.75
Haematological cancer: Where are we now with the treatment of multiple myeloma? Nat Rev Clin Oncol (2017) 0.75